Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAH-001
- Development stage
- Preclinical
- Lead developer
- Kahimmune Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
01
Overview
KAH-001 is a shared mRNA-based cancer vaccine being developed by Kahimmune Therapeutics, a spin-off from Gustave Roussy and SATT Paris-Saclay. The vaccine utilizes the proprietary Kahinomics™ platform to identify 'Kahigens™'—tumor-specific neoantigens derived from the 'dark genome' (non-coding regions) that are typically overlooked by traditional identification methods. Delivered via lipid nanoparticles (LNP), the mRNA encodes these dark genome-derived antigens to elicit a robust anti-tumor immune response. KAH-001 is designed as a companion therapy to be used in combination with existing cancer treatments to improve patient survival and quality of life. It is currently in preclinical development for the treatment of colorectal and pancreatic cancers.
- Other names
- Kahigens-based mRNA vaccineKahigens-based mRNA cancer vaccineKahigens/Pioneer Translation Products mRNA vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on KAH-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAH-001.